

# The genetic association between *iNOS* and *eNOS* polymorphisms and gastric cancer risk: a meta-analysis

Yi Zhu\*

Honggang Jiang\*

Zhiheng Chen

Bohao Lu

Jin Li

Yuping Peng

Xuning Shen

Department of Gastroenterological Surgery, The First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China

\*These authors contributed equally to this work

**Objective:** There are a number of susceptible factors for an increased risk of gastric cancer. Nitric oxide (NO) is considered to be associated with the development of a range of cancers. In particular, inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) are known to play a central role in the production of NO. Published studies relating to the association between *eNOS* rs1799983, rs2070744, and *iNOS* rs2297518 polymorphisms and the risk of gastric cancer risk are conflicting and inconclusive and require further analysis.

**Materials and methods:** This study involved a meta-analysis of case-control studies relating to *eNOS* rs1799983, rs2070744, and *iNOS* rs2297518 polymorphisms published prior to January 2018. Literature searches were carried out in PubMed, Embase, Web of Science, the Cochrane Library databases, and the Chinese National Knowledge Infrastructure. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of association based on genotype data.

**Results:** A total of 1,356 cases and 1,791 controls were included from nine case-control studies involving *eNOS* rs1799983 (G894T), rs2070744 (T-786C), and *iNOS* rs2297518 (C150T) polymorphisms. Data analysis indicated that *iNOS* rs2297518 was a risk factor for *Helicobacter pylorus*-positive gastric cancer when compared with *H. pylorus*-negative gastric cancer ( $p=0.003$ , OR [95% CI]=2.19 [1.31–3.66]). In addition, the allelic, dominant, and recessive models of *eNOS* rs2070744 were significantly associated with a risk of gastric cancer (allelic model:  $p<0.00001$ , OR [95% CI]=0.23 [0.16–0.34]; dominant model:  $p<0.00001$ , OR [95% CI]=0.25 [0.15–0.42]; recessive model:  $p<0.00001$ , OR [95% CI]=0.16 [0.08–0.30]). No association was identified between *eNOS* rs1799983 and the risk of gastric cancer ( $p>0.05$ ).

**Conclusion:** *iNOS* rs2297518 and *eNOS* rs2070744 polymorphisms may represent susceptible factors for gastric cancer.

**Keywords:** inducible nitric oxide synthase, iNOS, endothelial nitric oxide synthase, eNOS, gastric cancer, meta-analysis

## Introduction

Gastric cancer is one of the leading causes of mortality worldwide.<sup>1,2</sup> Multiple factors contribute to the pathogenesis of gastric cancer including genetic parameters, epigenetic predisposition, and environmental risk factors.<sup>3–5</sup> Previous studies have reported that *Helicobacter pylorus* is the most common risk factor in the pathology of gastric cancer.<sup>6,7</sup> However, one study showed that while 50% of the study population was infected with *H. pylorus*, the proportion of patients infected with *H. pylorus* who went on to develop gastric cancer was <5%.<sup>8</sup> Notably, in South Africa, where the incidence of *H. pylorus* is known to be higher than other areas of the world, the morbidity of

Correspondence: Yi Zhu  
Department of Gastroenterological Surgery, The First Affiliated Hospital of Jiaxing University, No. 1882, South Central Road, Jiaxing, Zhejiang, People's Republic of China  
Tel +86 139 6735 0889  
Email zhuanywen456@163.com

gastric cancer was shown to be relatively low.<sup>9</sup> Thus, it is important that we investigate the potential association between genetic predisposition and gastric cancer.

Recent research studies have focused on nitric oxide (NO), a short-lived, small molecule, generated from the physiological transformation of L-arginine to L-citrulline by nitric oxide synthase (NOS).<sup>10,11</sup> NO plays an important role in vasodilatation,<sup>12</sup> smooth muscle relaxation,<sup>13</sup> immunity,<sup>14</sup> and tumor angiogenesis.<sup>15</sup> Four isoforms of NOS have been identified and described as inducible nitric oxide synthase (iNOS), neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS), and mitochondrial nitric oxide synthase (mNOS).<sup>16</sup> eNOS is a calcium (Ca<sup>2+</sup>)-dependent enzyme and was first identified in vascular endothelial cells.<sup>17</sup> It has also been shown that eNOS regulates blood pressure, platelet aggregation, leukocyte adherence, and vascular smooth muscle cell mitogenesis and angiogenesis.<sup>18–20</sup> Furthermore, iNOS is one of the most important enzymes involved in the metabolic pathway of reactive oxygen and nitrogen species in the presence of *H. pylorus* infection.<sup>21</sup> It is also important to note that iNOS can produce larger amounts of NO than either eNOS or nNOS.<sup>22</sup>

eNOS is encoded by the *NOS3* gene, located in 7q35-q36, and encodes a protein of 1,203 amino acids.<sup>23</sup> To date, a number of polymorphisms have been reported for the *NOS3* gene, including rs1799983, intron 4a/b, and rs2070744; all these have been investigated for their association with the risk of gastric cancer.<sup>24,25</sup> Significant associations were detected between *eNOS* rs2070744 and the risk of gastric cancer in two different populations.<sup>25,26</sup> However, no genetic association was observed between *eNOS* rs1799983 and the risk of gastric cancer in Guilan and Chinese populations.<sup>25,27</sup> In terms of the *iNOS* gene, the rs2297518 polymorphism in exon 16 results in an amino acid substitute, Ser608Leu, and has been reported to be associated with cigarette- and alcohol-induced gastric cancer in the Chinese population<sup>28</sup> and *H. pylorus*-related gastric cancer in Iran.<sup>29</sup> However, these results were inconsistent and inconclusive.

Considering the limited number of subjects included in previous studies and the inconsistent results arising from different populations, we performed this meta-analysis in order to combine all pertinent published studies and investigate the precise association between *eNOS* rs2070744, rs1799983, and *iNOS* rs2297518 and the pathogenesis of gastric cancer.

## Materials and methods

### Publication searches and selection criteria

This meta-analysis followed the Cochrane collaboration definition and PRISMA 2009 guidelines for meta-analyses

and systematic reviews.<sup>30</sup> Literature searches were carried out in PubMed, Embase, Web of Science, the Cochrane Library databases, and the Chinese National Knowledge Infrastructure. We searched for all relevant publications exploring the relationship between iNOS and eNOS polymorphisms and the risk of gastric cancer (until January 1, 2018). The following were used as search terms: “*iNOS*” or “Inducible nitric oxide synthase” and “*eNOS*” or “endothelial nitric oxide synthase” or “*NOS3*” or “nitric oxide synthase 3” and “polymorphism” or “variation” and “gastric cancer” or “stomach cancer” or “gastric adenocarcinoma.” Our search was not limited by language. In addition, other potentially relevant items of literature were identified by cross-reference within eligible studies.

### Inclusion criteria

Studies were included if 1) they had a case–control design; 2) they contained sufficient data to calculate an odds ratio (OR) with a 95% CI; 3) they referred to the association between iNOS and eNOS polymorphisms and the risk of gastric cancer; and 4) the genotypic distributions in control groups were in Hardy–Weinberg equilibrium (HWE).

### Exclusion criteria

Studies were excluded if 1) they were duplicated studies, abstracts, letters, reviews, or papers presented in a meeting; 2) if they were unrelated to the genetic association between *iNOS* and *eNOS* polymorphisms and gastric cancer; 3) if there was insufficient genotype data; and 4) if the control group was not in HWE.

### Data extraction and quality assessment

Two authors (Jiang and Chen) extracted the data independently. Information arising from each individual study were summarized as follows: first author, year of publication, ethnicity, case and control, mean ages, gender (proportion of males), genotyping methods, sample source, HWE for control groups, state of *H. pylorus*, and the number of patients who smoked or suffered from alcoholism. All included studies were independently evaluated by using the Newcastle–Ottawa Scale<sup>31</sup> by two authors (Lu and Li). Any discrepancies in the assessment were resolved by another author (Peng).

### Statistical analysis


The strength of the association between *iNOS* (rs2297518) and *eNOS* (rs2070744, rs1799983) polymorphisms and the risk of gastric cancer were evaluated by calculating

pooled ORs and their corresponding 95% CIs by using RevMan 5.1 (Copenhagen, Denmark) and Stata 12.0 (StataCorp LP, College Station, TX, USA). Heterogeneity was tested using  $\chi^2$ -based Q test and  $I^2$  statistics. When there was no significant heterogeneity across studies ( $I^2 < 50\%$ ), the fixed effects model (Mantel–Haenszel method) was used for meta-analysis. Otherwise, the random effects model (the DerSimonian and Laird method) was used. Sensitivity analysis was then performed to assess the stability of the results. Publication bias was detected using Begg's test and Egger's test.  $p < 0.05$  was considered to be statistically significant.

## Results

### Study selection and characteristics

As shown in Figure 1, a total of 354 relevant publications were retrieved from the selected databases. After screening the titles, 293 of these publications were excluded because they were not related to the genetic association between *iNOS* and *eNOS* polymorphisms and gastric cancer, six were removed due to duplication, 46 were removed because they were reviews, abstracts, letters, or editorials. Finally, nine studies<sup>21,24–29,32,33</sup> that met the required criteria were



**Figure 1** PRISMA flowchart of inclusion and exclusion of studies.

retained for meta-analysis, of which five studies referred to the specific association between *iNOS* rs2297518 and gastric cancer.<sup>21,28,29,32,33</sup> Two studies referred to the specific associations between *eNOS* rs2070744,<sup>24,26</sup> rs1799983,<sup>25,27</sup> and gastric cancer, respectively. The basic characteristics of the enrolled patients are shown in Table 1. The NOS quality assessment of the studies included in this meta-analysis is included in Tables 1 and S1. Only studies with NOS scores  $> 6$  were selected for this meta-analysis.

### Results of the meta-analysis

The distributions of *iNOS* rs2297518 in allelic, dominant, and recessive models in the case group were not significantly different from that in the control group (allelic model:  $p = 0.73$ , OR [95% CI] = 1.09 [0.67–1.75]; dominant model:  $p = 0.87$ , OR [95% CI] = 1.03 [0.72–1.48]; recessive model:  $p = 0.83$ , OR [95% CI] = 1.16 [0.31–4.32]) (Figure 2; Table 2). Subgroup analysis, stratified by tests involving an anti-*H. pylorus* immunoglobulin G (IgG) antibody showed that the dominant model of *iNOS* rs2297518 was significantly associated with the risk of gastric cancer in *H. pylorus* CagA-positive cases ( $p = 0.003$ , OR [95% CI] = 2.19 [1.31–3.66]), but not in gastric cancer patients who were *H. pylorus* CagA-negative ( $p = 0.82$ , OR [95% CI] = 0.96 [0.65–1.41]) (Table 2).

For *eNOS* rs2070744, significant associations were detected between the allelic, dominant, and recessive models of *eNOS* rs2070744 (allelic model:  $p < 0.00001$ , OR [95% CI] = 0.23 [0.16–0.34]; dominant model:  $p < 0.00001$ , OR [95% CI] = 0.25 [0.15–0.42]; recessive model:  $p < 0.00001$ , OR [95% CI] = 0.16 [0.08–0.30]) (Figure 3; Table 2). However, the frequencies of allelic, dominant, and recessive models for *eNOS* rs1799983 were not significantly different when compared between case and control groups ( $p > 0.05$ ), which showed no significant correlation between *eNOS* rs1799983 and the risk of gastric cancer (Figure 4; Table 2). Because of a lack of data, it was not possible to perform subgroup analyses based on ethnicity, anti-*H. pylorus* IgG antibody status, smoking, and alcoholism.

### Sources of heterogeneity

Significant heterogeneity was observed for allelic, dominant, and recessive models of *iNOS* rs2297518 (allelic model:  $I^2(\%) = 83$ , dominant:  $I^2(\%) = 60$ , and recessive model:  $I^2(\%) = 76$ ) (Table 2). This level of heterogeneity was contributed predominantly by two studies.<sup>28,33</sup> Removal of these two studies from our meta-analysis resulted in 0% ( $p = 0.90$ ) heterogeneity, thus showing that this had the highest effect on association between *iNOS* rs2297518 and the risk of gastric cancer.

Table 1 The characteristics of individual studies

Genes	Study	Year	Ethnicity	Case/control	Male, %	Age (mean $\pm$ SD)	Genotyping	Sample source	<i>H. pylori</i> CagA (positive/negative)	Smoking	Alcoholism	HWE in control	Quality scores
<i>iNOS</i>	Shen et al <sup>32</sup>	2004	Chinese	143/246	66.67/64.41	59.36 $\pm$ 9.29/51.89 $\pm$ 10.24	PCR-RFLP	HB	29/115:95/83	54/33	43/38	Yes	8
<i>C105T</i>	Goto et al <sup>21</sup>	2006	Japanese	202/454	66.3/77.7	NA	PCR-RFLP	HB	NA	NA	NA	Yes	6
	Raffaei et al <sup>29</sup>	2012	Iran	159/170	53.0/58.0	61.32 $\pm$ 12.5/58.86 $\pm$ 14.2	ARFLP	HB	94/65:77/93	33/22	NA	Yes	8
	Shen et al <sup>28</sup>	2002	Chinese	143/246	NA	NA	PCR-RFLP	HB	1/2:14/53	NA	NA	Yes	6
	Yu et al <sup>33</sup>	2017	Chinese	80/140	NA	NA	NA	HB	NA	NA	NA	Yes	6
<i>eNOS</i>	Arjmand et al <sup>25</sup>	2014	Gulian	87/90	NA	NA	PCR-RFLP	HB	NA	NA	NA	Yes	6
G894T	Chen et al <sup>27</sup>	2010	Chinese	324/200	76.0/71.5	58.89 $\pm$ 7.87/57.74 $\pm$ 8.19	PCR-RFLP	HB	NA	NA	NA	Yes	7
<i>eNOS</i>	Tecder et al <sup>24</sup>	2010	Turkey	50/95	56.0/NA	59.27 $\pm$ 11.93/NA	PCR-RFLP	PB	NA	NA	NA	NA	7
C786T	Krishnaveni et al <sup>26</sup>	2015	Indian	150/150	43.3/42.0	NA	PCR-RFLP	HB	2/148:14/136	113/32	125/64	Yes	7

**Abbreviations:** *iNOS*, inducible nitric oxide synthase; *eNOS*, endothelial nitric oxide synthase; NA, not available; ARFLP, artificial restriction fragment length polymorphism; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PB, population-based; HWE, Hardy-Weinberg equilibrium; QA, quality assessment; *H. pylori*, *Helicobacter pylori*; SD, standard deviation.

## Sensitivity analysis and publication bias


Sensitivity analysis was performed to assess the influence of an individual study on the overall OR. Analyses showed that ORs were not significantly altered for *iNOS* rs2297518, *eNOS* rs2070744, or rs1799983 (Figure 5). This evidence indicated that the present results were statistically stable and reliable. Funnel plots, Begg's test, and Egger's test were additionally performed to assess publication bias; results revealed that there was no obvious publication bias in our overall analysis for *iNOS* rs2297518 ( $p_{\text{egger}}=0.564$ ;  $p_{\text{begg}}=0.327$ ) and *eNOS* rs1799983 ( $p_{\text{egger}}=0.511$ ;  $p_{\text{begg}}=0.602$ ) (Figure 6; Table 3).

## Discussion

In the present meta-analysis, we investigated the genetic associations between *iNOS* rs2297518, *eNOS* rs2070744, and rs1799983 and the risk of gastric cancer. Our combined results showed that the dominant model of *iNOS* rs2297518 was significantly associated with *H. pylori*-positive gastric cancer risk. In addition, *eNOS* rs2070744, but not rs179998, was identified as susceptible factor for the risk of gastric cancer.

Interestingly, the rs2297518 polymorphism in the *iNOS* gene has been reported to be associated with an increased risk for genotype gastric cancer in Asian populations,<sup>33</sup> but not in Iran<sup>29</sup> or Japanese populations.<sup>21</sup> Our meta-analysis failed to find any statistically significant relationship between the allelic, dominant, and recessive models of *iNOS* rs2297518 and the risk of gastric cancer. However, the distribution of the dominant model of *iNOS* rs2297518 among the *H. pylori*-positive gastric cancer group of patients and the *H. pylori*-negative gastric cancer group of patients was statistically significant, which indicated that *H. pylori* infection might play a key role in the development of gastric cancer. Epidemiological studies have also indicated that *H. pylori* infection is a risk factor for gastric cancer.<sup>34,35</sup> However, most patients with *H. pylori* infection do not appear to develop gastric cancer. The reasons for this inconsistency remain unclear and cannot be explained by bacterial virulence factors alone.

*iNOS* is shown to be upregulated in response to *H. pylori* infection and leads to excessive release of NO which would then contribute to the development of gastric atrophy.<sup>21</sup> An earlier hypothesis suggested that a higher level of *iNOS* can cause more oxidative DNA damage, thus increasing the risk of cancer development.<sup>36</sup> A number of reports have addressed the high expression of *iNOS* in gastric cancer, which is known to increase as the stage of cancer increases and with lymph node metastasis.<sup>37,38</sup> Previous research has shown that *iNOS* contributes to *H. pylori*-associated gastric carcinogenesis and that *H. pylori* is associated with




**Figure 2** Forest plots of odds ratios for the association between iNOS C150T and gastric cancer. (A) Allelic model; (B) dominant model; (C) recessive model. Abbreviations: iNOS, inducible nitric oxide synthase; CI, confidence interval.


**Table 2** The main results of the association between eNOS 894G>T, -786T>C, and iNOS C150T polymorphisms and gastric cancer

SNPs (minor allele)	Genetic model	Number of studies	Numbers		Test of association		Model	Test of heterogeneity	
			Case	Control	OR (95% CI)	p-value		p-value	I <sup>2</sup> (%)
iNOS C150T	T	5	1,454	2,512	1.09 (0.67–1.75)	0.73	R	<0.0001	83
	TT/CT+CC	5	727	1,256	1.16 (0.31–4.32)	0.83	R	0.002	76
	TT+CT/CC	5	727	1,256	1.03 (0.72–1.48)	0.87	R	0.04	60
	<i>H. pylorus</i> positive	3	126	181	2.19 (1.31–3.66)	0.003	F	0.22	34
	<i>H. pylorus</i> negative	3	226	402	0.96 (0.65–1.41)	0.82	F	0.20	38
eNOS G894T	T	3	914	776	0.80 (0.62–1.03)	0.09	F	0.57	0
	TT/GT+GG	3	457	388	0.52 (0.22–1.25)	0.14	F	0.56	0
	TT+GT/GG	3	457	388	0.79 (0.59–1.07)	0.13	F	0.60	0
eNOS C786T	T	2	400	482	0.23 (0.16–0.34)	<0.00001	F	0.38	0
	TT/CT+CC	2	200	241	0.16 (0.08–0.30)	<0.00001	F	0.52	0
	TT+CT/CC	2	200	241	0.25 (0.15–0.42)	<0.00001	F	0.41	0


Abbreviations: iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; OR, odds ratio; CI, confidence interval; R, random model; F, fixed model; NA, not available.



**Figure 3** Forest plots of odds ratios for the association between eNOS C786T and gastric cancer. (A) Allelic model; (B) dominant model; (C) recessive model. Abbreviations: eNOS, endothelial nitric oxide synthase; CI, confidence interval.



**Figure 4** (Continued)




**Figure 4** Forest plots of odds ratios for the association between eNOS G894T and gastric cancer. (A) Allelic model; (B) dominant model; (C) recessive model. **Abbreviations:** eNOS, endothelial nitric oxide synthase; CI, confidence interval.


non-cardiac tumors but not with cardiac tumors.<sup>39</sup> Several studies have also demonstrated a link between *iNOS* polymorphism and the risk of gastric cancer development. For example, Rafei et al<sup>29</sup> reported a significant association between a TT+CT genetic model and *H. pylorus*-positive gastric cancer. However, research conducted by Goto et al<sup>21</sup> and Shen et al<sup>32</sup> could not replicate this result. To our knowledge, the present study is the first to investigate and identify a significant association between *iNOS* rs2297518 and *H. pylorus*-positive gastric cancer risk, which implies that

the *iNOS* rs2297518 polymorphism might affect *H. pylorus* infection and iNOS expression. To confirm this result, it is now necessary to investigate a larger number of subjects in a case-control study.

Both iNOS and eNOS have been reported as an important form of NOS. The *eNOS* rs2070744 polymorphism was found to significantly reduce the rate of mRNA transcription, thus resulting in reduced levels of NO in the serum and stimulating tumor proliferation, angiogenesis, and metastasis.<sup>40</sup> The *eNOS* rs2070744 polymorphism has been reported to play



**Figure 5** Sensitivity analyses between eNOS C786T, G894T, and iNOS C150T and gastric cancer. (A) iNOS C150T; (B) eNOS C786T; (C) eNOS G894T. **Abbreviations:** eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase.



**Figure 6** Publication bias of literature for eNOS C786T, G894T, and iNOS C150T was tested by Begg's funnel plot and Egger's test. (A) iNOS C150T; (B) eNOS C786T; (C) eNOS G894T.

**Abbreviations:** eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; OR, odds ratio.

a critical role in cardiovascular disease,<sup>41</sup> breast cancer,<sup>42</sup> colorectal cancer,<sup>43</sup> and diabetic neuropathy.<sup>44</sup> Two previous meta-analyses have investigated the statistical genetic associations between *eNOS* rs2070744 and the risk of cancer; however, results differed between these two studies.<sup>45,46</sup> This inconsistency may have arisen due to the different number of studies included in two data sets. Two studies<sup>24,26</sup> included in the present analysis identified a significant association between the rs2070744 polymorphism and gastric cancer, and our combined results were the same as those of the individual studies, which might indicate a potential role for this

variant in the risk of gastric cancer. Notably, the results of the present meta-analysis relating to the correlation between the rs2070744 polymorphism and gastric cancer should be interpreted carefully because the number of studies included was relatively small.

The *eNOS* rs1799983 polymorphism is located in exon 7 of the *NOS3* gene and leads to the amino acid substitution, Glu298Asp, which alters susceptibility to cleavage, while also reducing enzyme activity and basal NO production.<sup>47</sup> Several previous meta-analyses<sup>48–50</sup> have investigated the association between the *eNOS* rs1799983 polymorphism and the risk of cancer, although most studies observed negative results. However, no meta-analysis has been conducted on the potential association between the *eNOS* rs1799983 polymorphism and gastric cancer. We included only two studies and found no statistical association of *eNOS* rs1799983 and the risk of gastric cancer, which indicates that the *eNOS* rs1799983 polymorphism might not be a risk factor for gastric cancer.

Although significant associations were detected between *iNOS* rs2297518, *eNOS* rs2070744, and the risk of gastric cancer, several limitations should be taken into account.

**Table 3** Egger's test and Begg's test for funnel plot asymmetries of iNOS and eNOS polymorphisms

Models of test	Polymorphisms	iNOS C150T	eNOS G894T	eNOS C786T
Egger's test	p-value	0.564	0.511	NA
	95% CI	-33.78177	-41.67948	NA
		to 22.38564	to 35.79079	
Begg's test	p-value	0.327	0.602	NA

**Abbreviations:** iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; OR, odds ratio; CI, confidence interval; NA, not available.



First, the number of studies and subjects included was relatively small. In particular, the association between *eNOS* rs2070744, rs1799983, and gastric cancer was investigated by only two studies enrolled by the present study; this might affect the reliability of our results. Thus, a larger number of studies, with more subjects, are now necessary to confirm our results. Second, the subjects in the present study were mostly of Asian origin. The prevalence of gastric cancer in Europeans and Latin Americans cannot be ignored. However, due to the lack of genetic association studies in Europeans and Latin Americans, we were not able to carry out subgroup analysis stratified by ethnicity. Third, apart from *H. pylorus* infection, smoking, diet, and alcohol abuse were also considered to be risk factors for gastric cancer, although we could not analyze the influence of these factors in regard to the risk of gastric cancer because of insufficient data.

## Conclusion

Our meta-analysis showed that the dominant model of *iNOS* rs2297518 may represent a risk factor for *H. pylorus*-positive gastric cancer, while *eNOS* rs2070744, but not rs1799983, represents a protective factor for the risk of gastric cancer. To confirm these results, a larger number of cohorts should be investigated, using a case-control design.

## Acknowledgment

This work was supported by the Foundation of Technology Institute of Jiaying city (2016BY28010) and the Foundation of the First Hospital of Jiaying (2017-YA-52).

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Zheng L, Wang L, Ajani J, Xie KP. Molecular basis of gastric cancer development and progression. *Gastric Cancer*. 2004;7(2):61–77.
- Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. *World J Gastroenterol*. 2015;21(34):9838–9852.
- Hudler P. Genetic aspects of gastric cancer instability. *ScientificWorldJ*. 2012;2012:761909.
- Koo SH, Jeong TE, Kang J, Kwon KC, Park JW, Noh SM. Prognostic implications for gastric carcinoma based on loss of heterozygosity genotypes correlation with clinicopathologic variables. *Cancer Genet Cytogen*. 2004;153:26–31.
- Jorge YC, Duarte MC, Silva AE. Gastric cancer is associated with NOS2-954GC polymorphism and environmental factors in a Brazilian population. *BMC Gastroenterol*. 2010;10:64.
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-first American cancer society award lecture on cancer epidemiology and prevention. *Cancer Res*. 1992;52:6735–6740.
- Komoto K, Haruma K, Kamada T, et al. Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. *Am J Gastroenterol*. 1998;93(8):1271–1276.

- Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. *J Pathol*. 2006;208(2):233–248.
- Danesh J. Is Helicobacter pylori infection a cause of gastric neoplasia? *Cancer Surv*. 1998;33:263–289.
- Kaji N, Horiguchi K, Iino S, et al. Nitric oxide-induced oxidative stress impairs pacemaker function of murine interstitial cells of Cajal during inflammation. *Pharmacol Res*. 2016;111:838–848.
- Iguchi H, Kojo S, Ikeda M. Nitric oxide (NO) synthase activity in the lung and NO synthesis in alveolar macrophages of rats increased on exposure to asbestos. *J Appl Toxicol*. 2015;16(4):309–315.
- Triggle CR, Lovren F, Jeffery TK, Gambino A, Wanstall JC. Nitric oxide, NO-donor mediated vasodilatation and redox regulation of vascular smooth muscle. *J Mol Cell Cardiol*. 2001;33(6):A157.
- Grange RW, Isotani E, Lau KS, Kamm KE, Huang PL, Stull JT. Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles. *Physiol Genomics*. 2001;5(1):35–44.
- Christian B. Nitric oxide synthase in innate and adaptive immunity: an update. *Trends Immunol*. 2015;36(3):161–178.
- Hasasna HE, Saleh A, Samri HA, et al. Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through inhibition of STAT3, NFκB and nitric oxide pathways. *Sci Rep*. 2016;6:21144.
- Xu M, Wei Q, Zheng K, et al. Protective effects of big-leaf mulberry and physiological roles of nitric oxide synthases in the testis of mice following water immersion and restraint stress. *Acta Histochem*. 2014;116(8):1323.
- Pott C, Steinritz D, Bölek B, et al. eNOS translocation but not eNOS phosphorylation is dependent on intracellular Ca<sup>2+</sup> in human atrial myocardium. *Am J Physiol Cell Physiol*. 2006;290(5):C1437.
- Cheng WH, Lu PJ, Hsiao M, et al. Renin activates PI3K-Akt-eNOS signalling through the angiotensin AT<sub>1</sub> and Mas receptors to modulate central blood pressure control in the nucleus tractus solitarii. *Br J Clin Pharmacol*. 2012;166(7):2024–2035.
- Kader KN, Akella R, Ziats NP, et al. eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation in vitro. *Tissue Eng*. 2000;6(3):241–251.
- Moldobaeva A, Rentsendorj O, Jenkins J, Wagner EM. Nitric oxide synthase promotes distension-induced tracheal venular leukocyte adherence. *PLoS One*. 2014;9(9):e106092.
- Goto Y, Ando T, Naito M, et al. Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population. *World J Gastroenterol*. 2006;12(39):6361–6365.
- Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. *Cell*. 1994;78:915–918.
- Nishank SS. Endothelial nitric oxide synthase (eNOS) gene polymorphism is associated with age onset of menarche in sickle cell disease females of India. *Mediterr J Hematol Infect Dis*. 2013;5(1):e2013036.
- Tecder ÜM, Karabulut HG, Gümüş-Akay G, et al. Endothelial nitric oxide synthase gene polymorphism in gastric cancer. *Turk J Gastroenterol*. 2010;21(4):338–344.
- Arjmand KZ, Salehi Z, Mashayekhi F, Najafi B, Mirpoor SH. Analysis of Glu298Asp eNOS gene polymorphism in patients with gastric cancer in the Guilan population. *Arak Med Univ J*. 2014;17(89):53–62.
- Krishnaveni D, Amar CB, Shravan KP, et al. Association of endothelial nitric oxide synthase gene T-786C promoter polymorphism with gastric cancer. *World J Gastrointest Oncol*. 2015;7(7):87–94.
- Chen SQ, Hong BB, Lin XD, Zhu JW, Tang Y, Lin JY. Association of the eNOS RS1799983 polymorphism with the development and progression of gastric cancer. *J Chongqing Med Univ*. 2010;35(12):1816–1819.
- Shen J, Wang R, Wang L, et al. Study on the relationship between susceptibility of stomach neoplasm cancer and polymorphism of inducible nitric oxide synthase gene. *Chin J Epidemiol*. 2002;23(5):374–377.
- Rafiei A, Hosseini V, Janbabai G, et al. Inducible nitric oxide synthetase genotype and Helicobacter pylori infection affect gastric cancer risk. *World J Gastroenterol*. 2012;18(35):4917–4924.

30. Boccia S. PRISMA: an attempt to improve standards for reporting systematic review and meta-analysis. *Ital J Public Health*. 2009;6(4): E352–E353.
31. Han Y, Xia Z, Guo S, Yu X, Li Z. Laparoscopically assisted anorectal pull-through versus posterior sagittal anorectoplasty for high and intermediate anorectal malformations: a systematic review and meta-analysis. *PLoS One*. 2017;12:e0170421.
32. Shen J, Wang RT, Wang LW, Xu YC, Wang XR. A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. *World J Gastroenterol*. 2004;10(22): 3278–3283.
33. Yu YH, Xian J, Chen CX. Analysis of relationship between iNOS polymorphisms and the susceptibility to gastric cancer. *J Clin Res*. 2017;34(1):23–25.
34. Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. *Dig Dis Sci*. 2010;55(11):3124–3131.
35. Barreto-Zuñiga R, Maruyama M, Kato Y, et al. Significance of Helicobacter pylori, infection as a risk factor in gastric cancer: serological and histological studies. *J Gastroenterol*. 1997;32(3): 289–294.
36. Chang CS, Chen WN, Lin HH. Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappa B expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected non-cardiac gastric adenocarcinoma. *World J Gastroenterol*. 2004;10(15):2232.
37. Song ZJ, Gong P, Wu YE. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. *World J Gastroenterol*. 2002;8(4):591–595.
38. Zhao Q, Liang XM, Wu QL, et al. Expression of iNOS and VEGF in breast cancer and its relationship with the axillary lymph node metastasis. *Cancer Prev Res*. 2004;31(9):545–547.
39. Lechner M, Rieder J, Tilg H. Helicobacter pylori infection, iNOS, and gastric cancer: the impact of another possible link. *J Surg Oncol*. 2007;95(3):271–272.
40. Nakayama M, Yasue H, Yoshimura M, et al. T 786 C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. *Circulation*. 1999;99:2864–2870.
41. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. *Am J Epidemiol*. 2006; 164:921–935.
42. Lee SA, Lee KM, Yoo KY, et al. Combined effects of antioxidant vitamin and NOS3 genetic polymorphisms on breast cancer risk in women. *Clin Nutr*. 2012;31(1):93–98.
43. Chihching Y, Santella RM, Lingling H, Fungchang S, Tang RP. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. *Int J Cancer*. 2009; 124(7):1565–1571.
44. Shah VN, Cheema BS, Kohli HS, Sharma R, Khullar M, Bhansali A. Endothelial nitric oxide synthase gene polymorphism and the risk of diabetic neuropathy in Asian Indian patients with type 2 diabetes. *J Diabetes Metab*. 2013;4:243.
45. Gao X, Wang J, Wang W, Zhang J. eNOS genetic polymorphisms and cancer risk: evidence from a meta-analysis and a case-control study of breast cancer. *Medicine*. 2015;94(26):e972.
46. Zhang L, Chen LM, Wang MN, et al. The Rs1799983, T-786c and 4b/a polymorphisms in Enos gene and cancer risk: a meta-analysis. *J Evid Based Med*. 2014;7(4):263–269.
47. Guidry MA, Kostek MA, Angelopoulos TJ, et al. Endothelial nitric oxide synthase (NOS3). *ISRN Vasc Med*. 2012;2012(9):901801.
48. Hao Y, Montiel R, Huang Y. Endothelial nitric oxide synthase (eNOS) 894 G>T polymorphism is associated with breast cancer risk: a meta-analysis. *Breast Cancer Res Treat*. 2010;124(3):809–813.
49. Hefler LA, Ludwig E, Lampe D, et al. Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. *Gynecol Oncol*. 2002; 86(2):134–137.
50. Jang MJ, Jeon YJ, Kim JW, et al. Association of eNOS polymorphisms (rs2070744, 4a4b, rs1799983) with colorectal cancer susceptibility in the Korean population. *Gene*. 2013;512(2):275–281.

## Supplementary material

**Table S1** Newcastle–Ottawa scale for quality assessment of included studies

Study	Year	Selection	Comparability	Outcome
Shen et al <sup>1</sup>	2004	***	**	**
Goto et al <sup>2</sup>	2006	***	**	*
Rafiei et al <sup>3</sup>	2012	***	**	***
Shen et al <sup>4</sup>	2002	***	*	**
Yu et al <sup>5</sup>	2017	***	*	**
Arjmand et al <sup>6</sup>	2014	***	*	**
Chen et al <sup>7</sup>	2010	***	**	**
Tecder et al <sup>8</sup>	2010	***	**	**
Krishnaveni et al <sup>9</sup>	2015	***	**	**

**Note:** The number of "\*" means the consistency of each study according to the Newcastle–Ottawa Scale.

## References

- Shen J, Wang RT, Wang LW, Xu YC, Wang XR. A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. *World J Gastroenterol*. 2004;10(22):3278–3283.
- Goto Y, Ando T, Naito M, et al. Inducible nitric oxide synthase polymorphism is associated with the increased risk of differentiated gastric cancer in a Japanese population. *World J Gastroenterol*. 2006;12(39):6361–6365.
- Rafiei A, Hosseini V, Janbabai G, et al. Inducible nitric oxide synthetase genotype and Helicobacter pylori infection affect gastric cancer risk. *World J Gastroenterol*. 2012;18(35):4917–4924.
- Shen J, Wang R, Wang L, et al. Study on the relationship between susceptibility of stomach neoplasm cancer and polymorphism of inducible nitric oxide synthase gene. *Chin J Epidemiol*. 2002;23(5):374–377.
- Yu YH, Jin Xian, Chen CX. Analysis of relationship between iNOS polymorphisms and the susceptibility to gastric cancer. *J Clin Res*. 2017;34(1):23–25.
- Arjmand KZ, Salehi Z, Mashayekhi F, Najafi B, Mirpoor SH. Analysis of Glu298Asp eNOS gene polymorphism in patients with gastric cancer in the Guilan population. *Arak Med Univ J*. 2014;17(89):53–62.
- Chen SQ, Hong BB, Lin XD, Zhu JW, Tang Y, Lin JY. Association of the eNOS RS1799983 polymorphism with the development and progression of gastric cancer. *J Chongqing Med Univ*. 2010;35(12):1816–1819.
- Tecder ÜM, Karabulut HG, Gümüş-Akay G, et al. Endothelial nitric oxide synthase gene polymorphism in gastric cancer. *Turk J Gastroenterol*. 2010;21(4):338–344.
- Krishnaveni D, Amar CB, Shravan KP, et al. Association of endothelial nitric oxide synthase gene T-786C promoter polymorphism with gastric cancer. *World J Gastrointest Oncol*. 2015;7(7):87–94.

### OncoTargets and Therapy

#### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress